Prothena Corporation plc (PRTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prothena Corporation plc (PRTA) has a cash flow conversion efficiency ratio of -0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.56 Million) by net assets ($294.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prothena Corporation plc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PRTA total liabilities for a breakdown of total debt and financial obligations.
Prothena Corporation plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prothena Corporation plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
More Provident Funds
TA:MPP
|
-0.116x |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
-0.094x |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
0.071x |
|
Capital Bancorp
NASDAQ:CBNK
|
0.082x |
|
Kido Group Corp
VN:KDC
|
0.061x |
|
Solid Biosciences LLC
NASDAQ:SLDB
|
-0.154x |
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
0.015x |
|
Ambassador Hotel Ltd
TW:2704
|
0.014x |
Annual Cash Flow Conversion Efficiency for Prothena Corporation plc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Prothena Corporation plc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see PRTA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $486.93 Million | $-150.05 Million | -0.308x | -29.19% |
| 2023-12-31 | $561.37 Million | $-133.91 Million | -0.239x | -36.35% |
| 2022-12-31 | $622.04 Million | $-108.82 Million | -0.175x | -188.04% |
| 2021-12-31 | $466.04 Million | $92.61 Million | 0.199x | +145.50% |
| 2020-12-31 | $184.01 Million | $-80.36 Million | -0.437x | -125.03% |
| 2019-12-31 | $272.92 Million | $-52.97 Million | -0.194x | -121.70% |
| 2018-12-31 | $323.00 Million | $-28.28 Million | -0.088x | +72.83% |
| 2017-12-31 | $407.19 Million | $-131.18 Million | -0.322x | -0.39% |
| 2016-12-31 | $365.40 Million | $-117.27 Million | -0.321x | -85.33% |
| 2015-12-31 | $360.67 Million | $-62.45 Million | -0.173x | -7249.70% |
| 2014-12-31 | $289.89 Million | $-683.00K | -0.002x | +98.73% |
| 2013-12-31 | $173.27 Million | $-32.10 Million | -0.185x | +44.31% |
| 2012-12-31 | $126.48 Million | $-42.07 Million | -0.333x | -110.87% |
| 2011-12-31 | $-6.44 Million | $-19.70 Million | 3.060x | +103.37% |
| 2010-12-31 | $100.00K | $-9.08 Million | -90.830x | -- |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more